Aethlon Medical, Inc.'s stockholders failed to approve Proposal No. 7 at the 2026 Annual Meeting, which sought to amend the Articles of Incorporation to authorize 20,000,000 additional shares of preferred stock. The proposal required a majority of outstanding common shares for approval but received only 204,122 votes in favor against 9,529 opposed and 184,547 broker non-votes. Consequently, the company's charter remains unchanged regarding preferred equity authorization. Aethlon Medical operates in the medical device industry, specializing in blood purification technologies.
